In a groundbreaking initiative aimed at enhancing both the health outcomes and financial sustainability of the NHS, researchers at Great Ormond Street Hospital (Gosh) are investigating the potential benefits of prescribing tablet medications over liquid forms for young patients. This shift could not only substantially reduce healthcare costs but also improve the quality of life for children affected by specific medical conditions.
Transitioning to Tablets: A Viable Solution
Recent findings from a study conducted at Gosh indicate that children as young as seven can successfully transition from liquid diazoxide to its tablet counterpart. This change is particularly relevant for patients suffering from congenital hyperinsulinism (CHI), a rare condition that requires frequent administration of medication to manage dangerously high insulin levels. The liquid form of diazoxide, costing £15.50 for 50mg, has been the standard treatment. However, researchers propose that moving to tablet formulations—which cost merely £1.15 for the same dosage—could save the NHS an estimated £40,000 per patient annually.
The study involved 19 children aged between seven and 13, who were closely monitored to ensure that their blood glucose levels remained stable during the transition. Feedback from participants highlighted a strong preference for the tablets, primarily due to their improved taste and ease of use. Jess Manktelow, an 11-year-old patient who switched to tablets in April 2025, expressed relief at no longer having to consume a medication she described as “horrible-tasting”.
Enhancing Patient Experience
The emotional and social implications of switching to tablet medication are profound. Children like Jess, who have structured their daily lives around the requirements of liquid medication, reported that tablets have simplified their routines, allowing them to engage more freely in activities such as school and sports. Jess shared her experiences of the challenges posed by her previous treatment, which required careful storage and frequent dosing. “It makes things very easy for me now,” she noted, reflecting on her newfound independence and control over her condition.
Jess’s mother, Steph Manktelow, articulated a common sentiment among families affected by chronic medical conditions. “We were so excited when the team told us we could switch to the diazoxide tablets. We’d been hoping for some time, knowing it was a better solution,” she stated, emphasising the importance of patient autonomy in managing health.
Future Research and Implications
The success of this initial project has prompted Gosh to consider further studies to evaluate whether even younger patients, starting from the age of four, can also benefit from the switch to tablets. Kate Morgan, a clinical nurse specialist involved in the research, highlighted the unexpected quality-of-life improvements noted during the trial. “Children are so much more than their diagnoses… it is very important we do all we can to make simple, positive changes,” she remarked.
Dr Antonia Dastamani, a consultant in paediatric endocrinology at Gosh and co-leader of the project, pointed out an important shift in pediatric care philosophy. Traditionally, discussions around medication have centred on more clinical aspects, such as administration methods or side effects. However, this study has illuminated the necessity of considering children’s preferences and experiences with medication, thus fostering a more patient-centred approach in treatment plans.
Why it Matters
The potential shift from liquid to tablet medications represents more than just a financial strategy for the NHS; it stands as a significant advancement in paediatric healthcare. By prioritising the preferences and experiences of young patients, healthcare providers can enhance treatment adherence and overall wellbeing. This initiative not only promises considerable cost savings but also highlights the importance of patient autonomy, setting a precedent for future healthcare innovations that prioritise both economic efficiency and improved quality of life for patients.
